Acute Renal Failure (Arf) (Acute Kidney Injury) - Market Access, Reimbursement Outlook, Competitive Landscape, Epidemiology and Forecast Report - 2015 To 2030

SKU ID : TLS-14435056 | Publishing Date : 01-Jan-2017 | No. of pages : 160

Partners "Acute Renal Failure (ARF) (Acute Kidney Injury)" - Market Access, Reimbursement Outlook, Competitive Landscape, Epidemiology and Forecast Report – 2015 to 2030" report comprises of the Disease overview, classifications, stages or severity level, pathogenesis, identified and emerging biomarkers, pipeline assessment, competitive landscape, KOLs perspective, Market access - Country Specific Regulatory scenarios, Patent landscape, reimbursement scenario; Public, Private, Medicare, Medicaid, Government, Private, Co-payment, Out of pocket, Epidemiology; Incidence, Prevalence, Mortality, and current therapy market share, Order of entry, patient share, Market uptake, Peak patient share, Disease burden, Annual cost of therapy, market forecast for USA, Germany, France, Italy, Spain, UK, Japan and China 2015 to 2030
Geographic Coverage
• United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan
• China
Market estimation: 2015 – 2030
Report brief:
This section provide the insights about historical and current patient pool (Incidence, Prevalence and mortality) and forecasted trend for 8 major markets (US, Germany, France, Italy, Spain, UK, Japan and China). The epidemiology research is one the key element of the report driven by meta-analysis, Systemic literature review and insights from KOL’s
Treatment Algorithm
The comprehensive details on country specific treatment and disease management for the patients in the US, Europe, Japan, and China. Future treatment paradigm and KOL’s perspective (HCP’s, Payers and Researcher) are the key strength of the report
Competitive Landscape
A thorough analysis of reported revenue, patient share and marketed trend for approved therapies however for pipeline assets we consider Phase I, Phase II and Phase III including their major milestones, study result, interim result, safety & efficacy data, key drivers, mechanism of action designation (Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review) geography level prioritization, asset level profile and probable launch date estimation
Market Outlook & Market Forecast
Historic, current and forecasted market trend (High, Base case, Low) of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better diagnosis of biomarkers. Key patient segment and market based on type, severity and stages of the disease. Disease burden, compliance rate, annual cost of therapy, reimbursement scenario, Patient share, Patient access
Market uptake and benchmarking
The market penetration for pipeline assets being derived on the basis of benchmarking the sales of launched assets specifically targeting the patient segment or overall indication or therapy area or country or region specific. Order of entry benchmark works as a critical element for defining the uptake curve for the pipeline assets. Many drug utilization study are being benchmarked to arrive at the current patient share for marketed therapies as well as off-label products. Market events are the major key factors which applied to the forecast model to optimize the year on year revenue estimation
Regulatory scenario
Country specific healthcare structure, regulatory bodies, HTA bodies, approval process for diagnostic and therapies, and work flow
Patent landscape
Country specific patent filings for approved therapies as well as pipeline assets, formulation patent, process patent (FDA, EMA, EPO, Orange book, JPO; Japan Patent Office) and fillings
Reimbursement Scenario
Country specific reimbursement Scenario; Public, Private, Medicare, Medicaid, Government, Private, Co-payment, Out of pocket
Key Report highlights
• 4 years of historical epidemiology data Epidemiology; Incidence, Prevalence, Mortality
• 11 years of epidemiology and market projections
• Incidence/ Prevalence patient population
• Mortality, survival and diagnosed patient pool
• Treated patient pool
• Treatment guidelines
• Competitive landscape (Marketed therapies, Off-label therapies, Pipeline assessment, Phase – I, II, III)
• Patient share
• Country specific revenue share and trend
• Market Opportunities assessment
• Key market and product event analysis
• Disease burden and annual cost of therapy
• Regulatory scenario
• Reimbursement Scenario
• Patent landscape
• HCP’s/ KOL’s perspective
• Payer’s perspective
• Analyst commentary Exponential Biotherapies, Lg Life Sciences, Alloksys, Angion Biomedica, Quark Pharmaceuticals, Am Pharma, Thrasos Therapeutics, Atoxbio

Frequently Asked Questions

This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
  • By product type
  • By End User/Applications
  • By Technology
  • By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.

  • market Reports market Reports